ES2053567T3 - Un procedimiento para la preparacion de una composicion farmaceutica de liberacion controlada. - Google Patents

Un procedimiento para la preparacion de una composicion farmaceutica de liberacion controlada.

Info

Publication number
ES2053567T3
ES2053567T3 ES87310427T ES87310427T ES2053567T3 ES 2053567 T3 ES2053567 T3 ES 2053567T3 ES 87310427 T ES87310427 T ES 87310427T ES 87310427 T ES87310427 T ES 87310427T ES 2053567 T3 ES2053567 T3 ES 2053567T3
Authority
ES
Spain
Prior art keywords
weight
assignment
pharmaceutical composition
velo
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87310427T
Other languages
English (en)
Inventor
Stewart Thomas Leslie
Sandra Therese Antoi Malkowska
Joanne Marchant
Philip John Neale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Application granted granted Critical
Publication of ES2053567T3 publication Critical patent/ES2053567T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

UNA COMPOSICION FARMACEUTICA DE CESION CONTROLADA, QUE COMPRENDE DIVERSOS ESFEROIDES RECUBIERTOS DE PELICULA, COMPRENDIENDO ESTOS UNA 3-ALQUILXANTINA, UN AGENTE ESFEROIZANTE NO SOLUBLE EN AGUA Y ENTRE 4 Y 9 % EN PESO DE AGUA, DONDE LA VELOCIDAD DE DISOLUCION IN VITRO DE LA 3-ALQUILXANTINA A PARTIR DE LOS ESFEROIDES REVESTIDOS DE PELICULA, CUANDO SE MIDE POR EL METODO USP DE PALETA USP A 100 RPM EN 900 ML DE TAMPON ACUOSO (PH 6,5 A 37 (GRADOS) C) ESTA ENTRE 7,5 Y 25,0 % EN PESO DE CESION DESPUES DE 1 H, ENTRE 22,5 Y 45,0 % EN PESO DE CESION DESPUES DE 2 H, ENTRE 40,0 Y 60,0 % EN PESO DESPUES DE 3 H, ENTRE 50,0 Y 75,0 % EN PESO DE CESION DESPUES DE 4 H, ENTRE 70,0 Y 92,5 % EN PESO DE CESION DESPUES DE 6 H, Y ENTRE 80,0 Y 100 % EN PESO DE CESION DESPUES DE 8 H. PREFERIBLEMENTE EL CONTENIDO EN AGUA ESTA ENRE 4 Y 8 %, ESPECIALMENTE ENTRE 4 Y 7 % EN PESO, DE LA FORMULACION DE ESFEROIDE RECUBIERTO DE PELICULA. LA 3-ALQUILXANTINA PREFERIDA ES TEOFILINA (ANHIDRA O HIDRATO), MIENTRAS QUE EL AGENTEESFEROIZANTE PREFERIDO ES CELULOSA MICROCRISTALINA.
ES87310427T 1986-12-02 1987-11-26 Un procedimiento para la preparacion de una composicion farmaceutica de liberacion controlada. Expired - Lifetime ES2053567T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868628728A GB8628728D0 (en) 1986-12-02 1986-12-02 Spheroids

Publications (1)

Publication Number Publication Date
ES2053567T3 true ES2053567T3 (es) 1994-08-01

Family

ID=10608274

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87310427T Expired - Lifetime ES2053567T3 (es) 1986-12-02 1987-11-26 Un procedimiento para la preparacion de una composicion farmaceutica de liberacion controlada.

Country Status (12)

Country Link
US (1) US4844910A (es)
EP (1) EP0270305B1 (es)
JP (1) JP2568230B2 (es)
AT (1) ATE84706T1 (es)
AU (1) AU596249B2 (es)
CA (1) CA1296254C (es)
DE (1) DE3783739T2 (es)
DK (1) DK630287A (es)
ES (1) ES2053567T3 (es)
GB (1) GB8628728D0 (es)
IE (1) IE59942B1 (es)
ZA (1) ZA878601B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813064D0 (en) * 1988-06-02 1988-07-06 Euro Celtique Sa Controlled release dosage forms having defined water content
CA2007055A1 (en) * 1989-01-06 1990-07-06 Garth Boehm Theophylline dosage form
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
DE3929864A1 (de) * 1989-09-08 1991-03-14 Nordmark Arzneimittel Gmbh Verfahren zur herstellung von theophyllin-pellets
EP0418597A3 (en) * 1989-09-21 1991-11-27 American Cyanamid Company Controlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
SE9002017D0 (sv) * 1990-06-06 1990-06-06 Kabivitrum Ab Process for manufacture of matrices
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
SE9301220D0 (sv) * 1993-04-14 1993-04-14 Kabi Pharmacia Ab Manufacturing matrices
US5569467A (en) * 1993-05-15 1996-10-29 Societe De Conseils De Recherches Et D'applications (S.C.R.A.S.) Process for the preparation of microballs and microballs thus obtained
US5413690A (en) * 1993-07-23 1995-05-09 Boehringer Mannheim Corporation Potentiometric biosensor and the method of its use
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
EP1041988A4 (en) * 1997-12-22 2002-03-13 Euro Celtique Sa METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP1041987B1 (en) 1997-12-22 2006-04-19 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrexone
EP2092936B1 (en) 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
GB0025208D0 (en) 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
EP1387673B1 (en) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
SI1416842T1 (sl) 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
IL160222A0 (en) 2001-08-06 2004-07-25 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist
HUE032656T2 (en) 2002-04-05 2017-10-30 Euro Celtique Sa Pharmaceutical composition containing oxicodone and naloxone
KR100628263B1 (ko) * 2002-08-21 2006-09-27 엘지.필립스 엘시디 주식회사 액정표시소자
CN1703200B (zh) 2002-09-20 2012-02-29 奥尔制药公司 隔离亚单元和相关组合物及方法
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
WO2004112756A1 (en) 2003-06-26 2004-12-29 Isa Odidi Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CN101115409B (zh) * 2005-02-04 2013-03-27 菲利普莫里斯生产公司 具有纤维质滋味添加剂的香烟及过滤嘴
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA2648280C (en) * 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
SI2719378T1 (sl) 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
SG174286A1 (en) 2009-03-10 2011-10-28 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
CN105193738B (zh) * 2015-09-21 2018-09-04 珠海市东辰制药有限公司 一种微晶纤维素丸芯的制备工艺

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US3576759A (en) * 1968-04-12 1971-04-27 Ncr Co Process for en masse production of spherules by desiccation
US3965256A (en) * 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
JPS56122311A (en) * 1980-02-29 1981-09-25 Eisai Co Ltd Lasting theophylline pharmaceutical composition
US4587118A (en) * 1981-07-15 1986-05-06 Key Pharmaceuticals, Inc. Dry sustained release theophylline oral formulation
FR2535202B1 (fr) * 1982-11-03 1985-08-09 Fabre Sa Pierre Comprimes de theophylline a liberation controlee et leur procede de fabrication
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
ATE29392T1 (de) * 1983-06-22 1987-09-15 Univ Ohio State Res Found Herstellung eines feinteiligen materials und verkapselung.
ZA859645B (en) * 1984-12-21 1986-08-27 Byk Gulden Lomberg Chem Fab Theophylline sustained release formulation
IE58246B1 (en) * 1984-12-21 1993-08-11 Byk Gulden Lomberg Chem Fab Theophylline sustained release formulation
EP0222883A1 (en) * 1985-05-15 1987-05-27 Riker Laboratories, Inc. Sustained release theophylline compositions and processes
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation

Also Published As

Publication number Publication date
EP0270305B1 (en) 1993-01-20
JPS63154620A (ja) 1988-06-27
AU8199787A (en) 1988-06-02
EP0270305A2 (en) 1988-06-08
CA1296254C (en) 1992-02-25
DE3783739D1 (en) 1993-03-04
EP0270305A3 (en) 1990-10-10
DK630287A (da) 1988-06-03
US4844910A (en) 1989-07-04
IE873105L (en) 1988-06-02
ZA878601B (en) 1988-05-11
IE59942B1 (en) 1994-05-04
GB8628728D0 (en) 1987-01-07
ATE84706T1 (de) 1993-02-15
AU596249B2 (en) 1990-04-26
JP2568230B2 (ja) 1996-12-25
DK630287D0 (da) 1987-12-01
DE3783739T2 (de) 1993-05-13

Similar Documents

Publication Publication Date Title
ES2053567T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica de liberacion controlada.
FI20070282A7 (fi) Hallitusti vapautuvan, selluloosaeetteriä sisältävän matriisimateriaalin käyttö
ES2058111T3 (es) Composicion de liberacion controlada de dihidrocodeina.
BE901359A (fr) Composition pharmaceutique a absorption reglee.
BG42000A3 (en) Method for preparing suspension of microcapsulated bacampicilline salt of acid incorporation
KR900015737A (ko) 배합물
ATE67933T1 (de) Hydromorphon-zusammensetzung mit gesteuerter wirkstofffreisetzung.
KR880004807A (ko) 수산화알루미늄을 함유하는 이부프로펜 조성물
KR890011609A (ko) 구충 분열체를 사용한 포자충증에 대한 생백신
ES2053989T3 (es) Un proceso para la preparacion de una forma de dosificacion oral, solida y de liberacion controlada.
KR900701325A (ko) 속방성 구강 투여용 정제
ES2174109T3 (es) Composicion antibacteriana para administracion oral.
BE901328A (fr) Composition pharmaceutique a absorption reglee.
ATE241987T1 (de) Diltiazem-zusammensetzungen mit kontrollierter wirkstoffabsorption
YU20050411A (sh) Komopzicije oksikodona sa kontrolisanim oslobadanjem
YU20050410A (sh) Kompozicije oksikodona sa kontrolisanim oslobađanjem

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 270305

Country of ref document: ES